

1 **Full title:** Local genetic covariance between serum urate and kidney function  
2 obtained from local Bayesian regressions.

3 **Short Title:** Shared genetics of comorbidities

4  
5 Alexa S Lupi<sup>1,2</sup>, Nicholas A Sumpter<sup>3</sup>, Megan P Leask<sup>3,4</sup>, Justin O’Sullivan<sup>5</sup>, Tayaza Fadason<sup>5</sup>,  
6 Gustavo de los Campos<sup>1,2,6</sup>, Tony R Merriman<sup>3</sup>, Richard J Reynolds<sup>3\*</sup>, Ana I Vazquez<sup>1,2\*</sup>

7  
8 <sup>1</sup> Department of Epidemiology and Biostatistics, Michigan State University (MSU), East  
9 Lansing, Michigan, United States

10 <sup>2</sup> Institute for Quantitative Health Science and Engineering, Systems Biology, MSU

11 <sup>3</sup> Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama,  
12 United States

13 <sup>4</sup> Department of Biochemistry, University of Otago, Dunedin, New Zealand

14 <sup>5</sup> Liggins Institute, The University of Auckland, Auckland, New Zealand

15 <sup>6</sup> Department of Statistics and Probability, MSU

16  
17 \* Corresponding authors

18 Email: [avazquez@msu.edu](mailto:avazquez@msu.edu) (AIV)

19 [richardreynolds@uabmc.edu](mailto:richardreynolds@uabmc.edu) (RJR)

20

21

22

23

## 24 **Abstract**

25           Hyperuricemia is associated with several cardiometabolic and renal diseases, such as gout  
26 and chronic kidney disease. Previous studies have examined the shared genetic basis of chronic  
27 kidney disease and hyperuricemia either using single-variant tests or estimating whole-genome  
28 genetic correlations between the traits. Individual variants typically explain a small fraction of  
29 the genetic correlation between traits, thus reducing the power to map pleiotropic loci.  
30 Alternatively, genome-wide estimates of genetic correlation, while useful, do not shed light on  
31 what regions may be implicated in the shared genetic basis of traits. Therefore, to fill the gap  
32 between these two approaches, we used local Bayesian regressions to estimate the genetic  
33 covariance between markers for chronic kidney disease and hyperuricemia in specific genomic  
34 regions. We identified 267 linkage disequilibrium segments with statistically significant  
35 covariance estimates, 17 of which had a positive directionality and 250 negative, the latter being  
36 consistent with the directionality of the overall genetic covariance. These 267 significant  
37 segments implicated 188 genetically distinct shared loci. Many of these loci validate previously  
38 identified shared loci with consistent directionality, including 22 loci previously identified as  
39 shared. Numerous novel shared loci were also identified, such as *THBS3/MTX1/GBAP1*,  
40 *LINC01101*, *SLC7A9/CEP89*, *CYP24A1*, *KCNS3*, *CHD9*, *ARL15*, *PAX8*, and *IGF1R*. Finally, to  
41 examine potential biological mechanisms for these shared loci, we have implicated a subset of  
42 the genomic segments that are associated with gene expression using colocalization analyses. In  
43 particular, five genes (*FGF5*, *ARL6IP5*, *TRIM6*, *BCL2L1*, and *NTRK1*) expressed in the kidney  
44 are causal candidates potentially contributing to pleiotropic pathways between chronic kidney  
45 disease and hyperuricemia. The regions identified by our local Bayesian regression approach

46 may help untangle and explain the association between chronic kidney disease and  
47 hyperuricemia.

48

## 49 **Author Summary**

50       Chronic kidney disease is of increased prevalence among people with hyperuricemia,  
51 suggesting a shared genetic etiology. Since markers for chronic kidney disease and  
52 hyperuricemia have an overall non-zero genetic correlation, there appears to be genetic basis to  
53 the shared etiology. However, genome-wide genetic correlation estimates do not elucidate the  
54 specific genomic regions contributing to both traits, particularly regions that contribute to the  
55 traits with opposite directionality to the overall directionality. We have implemented local  
56 Bayesian regressions to identify small genomic segments contributing to the overall genetic  
57 correlation. Our method is applicable to any pair of traits that have a shared genetic relationship.  
58 We have found numerous novel shared loci, validated previously reported loci, and identified  
59 new shared pathways simultaneously contributing to the markers between chronic kidney disease  
60 and hyperuricemia. These loci all merit detailed investigation as they may involve underlying  
61 biological mechanisms with the potential to explain the common pathogenesis of hyperuricemia  
62 and chronic kidney disease.

63

## 64 **Introduction**

65           Chronic kidney disease (CKD) carries a significant global health and economic burden  
66 [1,2]. In the United States alone, it is estimated that 37 million adults (~15%) have CKD and  
67 kidney diseases are the ninth leading cause of death [3]. CKD stages 3-5 manifest as decreased  
68 renal function and are defined by elevated serum creatinine (sCr) or estimated glomerular  
69 filtration rate (eGFR)  $<60 \text{ mL/min/1.73m}^2$ . CKD can lead to lower quality of life, increased risk  
70 of cardiovascular morbidity, and premature mortality [2]. Hyperuricemia is defined by serum  
71 urate (sU) concentration  $>6.8 \text{ mg/dL}$  and is contributed to by deteriorating renal function [3].  
72 Hyperuricemia has several comorbidities associated with it, including CKD [4], and can result in  
73 monosodium urate crystal deposits in joints and tendons, which leads to the development of gout.  
74 In the United States, an estimated 9.2 million people have gout (~ 4%), which is also associated  
75 with substantial cardiovascular morbidity and all-cause mortality [5–8]. Among people with  
76 hyperuricemia there is a higher prevalence of CKD, and among patients with CKD, sU  
77 concentrations are higher [9,10].

78           Genome-wide analyses have demonstrated that the association observed between eGFR  
79 and serum urate has a genetic basis. Tin *et al.* carried out a large-sample trans-ethnic genome-  
80 wide association study (GWAS) of sU and, through cross-trait linkage disequilibrium (LD) score  
81 regression, obtained an estimate of overall genetic correlation between eGFR and sU of -0.26  
82 (standard error of 0.04) [11]. This was one of the largest negative correlations with sU out of 748  
83 traits analysed [11]. Reynolds *et al.*, using two large family-based datasets and Bayesian whole-  
84 genome regressions, obtained global genetic correlations between sCr (which has a direct inverse  
85 relationship to eGFR, hence the directionality difference between the estimates) and sU of 0.20  
86 (95% confidence interval (CI): 0.07, 0.33) in one dataset and 0.25 (95% CI: 0.07, 0.41) in the

87 other [12]. However, the pleiotropic regions of the genome and biological mechanisms  
88 underlying the genetic relationship are unclear without identifying local genetic covariances [13].

89 GWAS of sU and eGFR have identified numerous loci associated with each phenotype  
90 separately. A recent study comparing large GWAS of the markers identified 35 shared loci [14].  
91 However, the GWAS methods used to detect the shared signals used single-marker regressions  
92 or tests, which are based on the marginal association of individual single-nucleotide  
93 polymorphisms (SNPs) with phenotypes and thus do not account for LD between SNPs. Our  
94 method improves over post-analysis of GWAS summary statistics by estimating neighbouring  
95 SNP effects concomitantly. Incorporating local LD to estimate genetic effects in a tightly  
96 segregating chromosomal segment has been previously suggested [15–17].

97 In this study, we mapped the shared genetic basis of eGFR and sU using local Bayesian  
98 regressions (LBR) that estimate local genetic variances and covariances and capture LD patterns  
99 [17]. Our aim was to characterize the common genetic basis for CKD (eGFR) and hyperuricemia  
100 (serum urate levels) to disentangle the relationship through the identification and preliminary  
101 examination of pleiotropic genomic regions. We estimated local genetic covariances between sU  
102 and eGFR genome wide. We identified numerous local genetic regions as significant for local  
103 genetic covariance, including previously implicated shared loci and novel shared loci.

## 104 **Results**

105           The study was based on the UK Biobank dataset and included 333,542 distantly related  
106 white participants, of whom 53.7% were female with an average age of  $56.9 \pm 8.0$  years old. The  
107 average sCr level was  $0.8 \pm 0.2$  mg/dL (the average  $\pm$  standard error), eGFR was  $144.2 \pm 56.0$   
108 ml/min/1.73 m<sup>2</sup>, and the average sU level was  $5.2 \pm 1.3$  mg/dL. Two (2.0) percent of the  
109 individuals had an ICD10 diagnosis or self-diagnosis of gout, 12.4% had hyperuricemia, 0.5%  
110 had CKD, and 0.3% had hyperuricemia and CKD. Our genetic analyses utilized directly  
111 genotyped autosomal SNPs from the UK Biobank Axiom™ Array by Affymetrix. After applying  
112 filters for minor-allele frequency  $\geq 1\%$  and for a missing call rate  $\geq 5\%$ , a total of 607,490 SNPs  
113 were used.

114           We identified 511,828 overlapping LD segments (small, non-independent chromosomal  
115 segments). Following Funkhouser *et al.* [17], we analysed the markers using a sequence of LBR,  
116 where each marker is regressed on contiguous SNPs in a large chromosomal segment plus  
117 overlapping flanking buffers (represented in S1 Fig). We collected the samples from the  
118 posterior distribution of effects for each LBR and used these samples to estimate the local  
119 variances for each marker (Fig 1) and the local covariances between the markers (Fig 2).  
120 Variances and covariances were computed within 511,828 LD segments identified. The LBRs  
121 were implemented using the BGLR R package [18], and had a variable selection prior  
122 distribution for the SNP effects with a point of mass at zero. A detailed description is provided in  
123 the Materials and Methods section.

124           Using a bootstrap resampling method, we obtained standard error estimates of the local  
125 genetic covariance estimates and found 267 LD segments where the covariance estimates had a  
126 95% CI that did not include zero (Fig 2; S1 Table). Due to the computational burden of

127 bootstrapping with a very large sample size, we preselected large genomic regions for  
128 bootstrapping if at least one SNP from a single-marker regression was significant for either sU or  
129 for a CKD marker (see methods for details and S2 Table for GWAS results). The number of  
130 SNPs in the significant LD segments ranged from one to 17, averaging 4.1 per segment (about  
131 0.02 MB, excluding the 87 single SNP segments). Interestingly, 17 of the 267 significant  
132 segments showed positive genetic covariance estimate directionality, and the remaining 250 were  
133 negative estimates. After a conservative Bonferroni correction for multiple testing (see materials  
134 and methods section), 18 segments were still significant (S1 Table).

135         The 267 significant LD segments often included the same variants and map to identical  
136 GWAS loci, so we collapsed these 267 segments to 188 unique loci that possess genetic  
137 covariance signal between eGFR and sU (S3 Table). The top distinct loci implicated by the  
138 significant segments in terms of covariance magnitude are listed in Table 1. A graphical  
139 representation of some of the top significant loci, *i.e.*, the top covariance magnitudes in  
140 significant distinct loci, is presented in Fig 3.

141

142 **Table 1.** The top magnitude genomic segments significant for covariance between sU and eGFR  
 143 with their chromosome, annotated name, effect size [95% CI], and colocalized eQTL.

Chr	Annotated Name	Segment Size (min-max SNPs)	Effect Size [LCL, UCL]*	Colocalized eQTL
11	<i>DCDC1</i>	10 rs963837-rs10767873	-0.786 [-0.918, -0.669]**	
7	<i>UNCX</i>	13 rs6950388-rs1880301	-0.536 [-0.676, -0.402]**	
7	<i>PRKAG2</i>	10 rs10224002-rs11771445	-0.440 [-0.607, -0.264]**	
6	<i>VEGFA</i>	1 rs881858	-0.368 [-0.488, -0.215]**	
8	<i>STC1</i>	6 rs62502212-rs1705690	-0.366 [-0.494, -0.233]**	
11	<i>OVOLI</i>	7 rs4014195-rs36008241	-0.316 [-0.460, -0.167]	<i>PCNX3, MAP3K11, SCYL1, RP-11-770G2.2, OVOLI, KRT8P26</i>
12	<i>R3HDM2/INH BC</i>	7 rs73115999-rs507562	-0.296 [-0.429, -0.126]	<i>R3HDM2</i>
1	<i>THBS3/MTX1/GBAPI</i>	5 rs35154152-rs2049805	-0.276 [-0.491, -0.072]	
2	<i>HOXD10</i>	5 rs847153-rs711818	-0.234 [-0.329, -0.145]**	
2	<i>LINC01101</i>	7 rs11122800-rs35932591	-0.211 [-0.299, -0.117]	
16	<i>LOC105371257</i>	1 rs12927956	-0.168 [-0.244, -0.094]	
2	<i>KCNS3</i>	3 rs9789415-rs4567937	-0.165 [-0.220, -0.108]**	
20	<i>CYP24A1</i>	4 rs4809954-rs2616278	-0.163 [-0.249, -0.070]	
2	<i>PAX8</i>	10 rs4849176-rs72831838	-0.155 [-0.247, -0.073]	
5	<i>ARL15</i>	17 rs67199213-rs11739045	-0.155 [-0.292, -0.022]	
16	<i>CHD9</i>	10 rs8049859-rs1984470	-0.155 [-0.792, -0.012]	
15	<i>IGF1R</i>	4 rs907808-rs12437561	-0.149 [-0.244, -0.034]	<i>IGF1R, NRCAM, TRAPPC10</i>
2	<i>DDX1</i>	7 rs807628-rs876718	-0.148 [-0.237, -0.076]	<i>DDX1</i>
7	<i>LOC730338</i>	5 rs700752-rs12537178	-0.140 [-0.224, -0.016]	
15	<i>NRG4</i>	1 rs8024155	-0.136 [-0.245, -0.048]	
3	<i>SLC15A2/ILDR1</i>	9 rs2049330-rs6438689	-0.129 [-0.220, -0.023]	<i>SLC15A2, CD86</i>



<b>15</b>	<i>SCAPER</i>	5 rs4886825-rs4442773	-0.129 [-0.512, -0.005]	
<b>2</b>	<i>MBD5</i>	4 rs11896010-rs10174206	-0.127 [-0.781, -0.00004]	<i>ACVR2A, MBD5, AC009480.3</i>
<b>9</b>	<i>PIP5K1B</i>	2 rs80095931- rs4744712	0.141 [0.013, 0.308]	<i>BAG1, PIP5K1B, RP11-203L2.3</i>
<b>10</b>	<i>AICF</i>	7 rs12413118-rs61856594	0.267 [0.101, 0.466]	<i>AICF</i>
<b>19</b>	<i>SLC7A9/CEP89</i>	16 rs78676942-rs11668957	0.321 [0.012, 0.608]	<i>SLC7A9</i>
<b>2</b>	<i>LRP2</i>	6 rs41268683-rs2075252	0.391 [0.093, 0.636]	
<b>2</b>	<i>CPS1</i>	1 rs1047891	0.391 [0.217, 0.585]	
<b>2</b>	<i>NRBP1/IFT172/FNDC4/GC KR</i>	16 Affx-19857019-rs1260333	0.586 [0.301, 0.890]	

144 \*Effect sizes and CIs were scaled by 1e4 for readability.

145 \*\*Also significant with normality-based, conservative multiple testing correction.

146 **Gene expression/eQTL analysis**

147 We used COLOC [19] and expression data from The Genotype Tissue Expression  
148 (GTEx) project (v8) [20] to identify candidate causal genes at significant local genetic  
149 covariance segments between sU and eGFR. Forty-one of the 188 distinct significant shared loci  
150 (21.8%) are shown to modify the expression of 90 candidate causal genes colocalized with the  
151 covariance signals (S4 Table). Of note are 5 genes with covariance signals and colocalized eQTL  
152 that are expressed in the kidney: *FGF5*, *ARL6IP5*, *TRIM6*, *BCL2L14* in *cis*, and *NTRK1* in *trans*.

153

154 **Validation**

155 We performed a validation analysis with the Atherosclerosis Risk in Communities Study  
156 (ARIC) utilizing 8,752 distantly related white subjects with 739,587 genotyped SNPs after  
157 standard quality controls on the phenotypes and genotypes. Some of the largest magnitude  
158 covariance estimates (*e.g.*, *SHROOM3*, *SLC15A2*, and *SLC2A9*) were validated in terms of effect  
159 size, though they were not necessarily loci significant for local genetic covariance, likely due to  
160 the substantially smaller sample size in ARIC compared to the UK Biobank. Similar to the  
161 covariance estimates, the variance estimates were validated only in the largest effect size loci,  
162 such as *SHROOM3* and *GATM* for eGFR variance, and *SLC2A9* and *ABCG2* for sU.

163

164

## 165 **Discussion**

166           The goal of this study was to infer the shared genetic architecture of sU (causal for gout),  
167 and eGFR (causal for CKD). Our results highlight genes that may be involved in the observed  
168 relationship between the traits. In this study, we utilized the large-scale UK Biobank and formal  
169 statistical inference from local Bayesian regression models to estimate local genetic covariances  
170 to identify shared loci. Our results demonstrated that genetic covariance between eGFR and sU  
171 was widespread across the genome. Our method identified 188 distinct LD segments with shared  
172 genetic effects between eGFR and sU, the majority of which agree with the global negative  
173 correlation directionality [11,12]. Many of the loci identified were previously only known to be  
174 associated with one of the two traits, demonstrating that the set of loci contributing to both traits  
175 is substantially larger than previously thought.

176           Out of the significant shared loci, almost all showed negative local genetic covariance  
177 estimates. This is consistent with the overall genetic covariance directionality [11,12], indicating  
178 that they either contribute to worsening kidney function (decreasing eGFR or higher sCr) and  
179 increasing sU, or *vice versa*. Interestingly, there were 10 significant shared loci with positive  
180 local genetic covariance estimates: *NRBP1/IFT172/FNDC4/GCKR*, *CPS1*, *SLC7A9/CEP89*,  
181 *AICF*, *PIP5K1B*, *BCAS3*, *B4GALT1*, *OR52H1/HBG2*, and *LRP2*, which had 2 distinct positive  
182 covariance loci. Positive covariance indicates that the genomic region either contributes to  
183 increasing sU and improved kidney function, or decreasing sU and worsening kidney function.  
184 Two of the 10 loci with a positive signal, *GCKR* and *CPS1*, are mainly expressed in the liver and  
185 one, *LRP2*, is mainly expressed in the kidney [20]. Segments that have directionality opposite of  
186 the overall genetic correlation are masked by the overall correlation estimate, but our local  
187 method can distinguish them.

188 Segments encompassing the *SLC2A9* locus had some of the largest local genetic  
189 covariance estimates and showed both positive and negative estimates. Urate transporters  
190 *SLC2A9* and *ABCG2* have the largest GWAS effect sizes for sU, accounting for a 4-5% of  
191 variance in sU [11,21–24]. However, only one small magnitude segment in *SLC2A9* was  
192 significant for covariance. Interestingly, one SNP in that segment is rs16890979, which is a  
193 missense variant that has been identified in numerous sU GWAS [25–27]. *ABCG2* also had LD  
194 segments with both positive and negative estimates of large magnitude, but no segments from the  
195 *ABCG2* locus were significant for covariance. Our results demonstrate that, with the exception of  
196 one segment, segments in both *SLC2A9* and *ABCG2* loci are associated with just sU levels, but  
197 are not pleiotropic regions for sU and eGFR. A similar phenomenon is observed with the largest  
198 magnitude eGFR gene, *SHROOM3*. That is, none of the segments found in *SHROOM3* were  
199 significant for local genetic covariance. This exemplifies that the loci driving the genetic  
200 correlation between these two traits are not necessarily the loci found from analysing the traits  
201 individually.

202 Previous research investigating pleiotropic genetic loci between serum urate and eGFR  
203 has implicated loci as shared if signals of association obtained from marginal single-marker  
204 regressions (*e.g.*, GWAS) for both traits are colocalized based [14]. Leask *et al.* [14] recently  
205 compared overlapping loci between two large GWAS, one of sU and the other kidney function  
206 [11,28], and found 35 independent colocalized loci. Our results validate 25 of these 35 loci, and  
207 all but 3 loci (*DACHI*, *CPS1*, and *INS-IGF2*) had covariance directionality that matched the  
208 directionality of effects found by Leask *et al.* [14]. The LBR method we utilized also identified  
209 numerous novel loci with significant local genetic covariance for sU and eGFR, including  
210 *LINC01101*, *KCNS3*, *CYP24A1*, *PAX8*, *ARL15*, *CHD9*, *IGF1R*, *PIP5K1B*, and *SLC7A9/CEP89*.

211 Our covariance approach has direct implications for assessing causal relationships  
212 between exposures using Mendelian randomization (MR). Pleiotropic genetic variants violate  
213 assumptions of univariate MR, however, they are useful in multivariable MR that can  
214 simultaneously assess the causal effects of multiple risk factors on an outcome [29]. For  
215 example, genetic variants from *SLC2A9* and *ABCG2* may be valid instrumental variables to use  
216 in MR to test for a causal effect of sU on CKD, however, the loci listed in Table 1 and S1 Table  
217 would not. In fact, *SLC22A11* has previously been identified as a pleiotropic variant that may  
218 improve kidney function through its activity in raising urate levels [23]. MR has previously been  
219 used to show that serum urate is not causal of CKD [30], however, Jordan *et al.* noted significant  
220 pleiotropy in the genetic variants used in their study, which they attempted to counter using MR  
221 techniques robust to pleiotropy. Of the 26 SNPs used by Jordan *et al.*, two were identified by us  
222 as shared (gene indicated next to the SNP), and six imputed variants were located within one of  
223 our significant pleiotropic regions (these SNPs were not in our genotyping platform), between sU  
224 and eGFR: rs1260326 (*GCKR*), rs17050272 (*LINC01101*), rs729761, rs10480300, rs10821905,  
225 rs3741414, rs1394125, and rs6598541.

226 Our eQTL analysis of the segments significant for local genetic covariance uncovered  
227 numerous genes of interest, such as *SLC7A9*, which encodes a solute transporter largely  
228 expressed in the small intestine, *AICF*, which encodes a protein involved in apolipoprotein B  
229 synthesis in the liver, and *TRIM6*, which encodes an E3 ubiquitin ligase involved in interferon  
230 gamma signalling and innate immune response with high expression levels in the kidney [20].  
231 The genes uncovered from the eQTL analysis will be particularly interesting for future study, as  
232 they will likely aid our understanding of the relationship between kidney function and sU.

233           This study had several strengths. Through our novel statistical approach of obtaining  
234 genetic covariance estimates from conditional LBR models in very large datasets, we have  
235 uncovered numerous novel genomic regions that can be defined as shared genetic regions for sU  
236 and eGFR. The approach presented in this paper was applied in the context of sU and eGFR, but  
237 it could be applied to any pair of continuous traits. While local genetic correlation estimates can  
238 theoretically be obtained from fitting local multivariate mixed models that utilize genetic and  
239 phenotypic information on sU and kidney function, a limitation is that with increasingly large  
240 datasets this is computationally challenging. Our method overcomes this limitation by enabling  
241 us to obtain local genetic covariance point estimates genome wide while still utilizing the large  
242 size of the UK Biobank.

243           The local shared genomic regions we have uncovered in this study can provide insight  
244 into the relationship between hyperuricemia and CKD, elucidating the biological mechanisms  
245 underlying the traits. This will help to further understanding of the genetic basis of  
246 hyperuricemia and CKD.

247

## 248 **Materials and Methods**

249 This study used 333,542 Caucasian unrelated subjects from the UK Biobank. Subjects  
250 missing phenotypes of interest for both of their two visits were excluded from the analysis. The  
251 UK Biobank used the custom UK Biobank Axiom™ Array by Affymetrix to genotype study  
252 participants [31]. Quality control involved removing SNPs that had a minor allele frequency less  
253 than 1% or a missing call rate greater than 5%, resulting in 607,490 autosomal chromosome (1-  
254 22) SNPs [32].

255

### 256 **Identification of unrelated samples**

257 We used the R package BGDData [33] to compute the expected proportion of allele sharing  
258 among UK Biobank individuals with the additive genomic relationship matrix  $\mathbf{G}$ ,

259  $\mathbf{G} = \frac{\mathbf{Z}\mathbf{Z}'}{\text{tr}(\mathbf{Z}\mathbf{Z}')/n}$ , where  $\mathbf{Z}$  is a matrix of centered genotypes. That is,  $\mathbf{Z}_{ij} = x_{ij} - 2p_j$  where  $x_{ij}$  is the

260 number of copies of the reference allele at the  $j^{\text{th}}$  loci of the  $i^{\text{th}}$  individual and  $p_j$  is the frequency  
261 of the reference allele of the  $j^{\text{th}}$  loci. In a homogeneous sample,  $g_{ij}$  (where  $i \neq j$ ) can be considered  
262 as an estimate of the relatedness between subjects  $i$  and  $j$ . If  $g_{ij} \geq 0.1$  they were excluded from the  
263 sample.

264

### 265 **Phenotypes**

266 sU and sCr data was obtained from the first visit. For the small number of participants  
267 (0.28%) that did not have phenotype data of interest collected at the first visit, we retrieved data  
268 from the second visit.

269 eGFR is an indicator of renal function and used to ascertain CKD. In this study, we  
270 defined eGFR using the abbreviated Modification of Diet in Renal Disease (MDRD) equation,

271 which uses fewer variables than others yet performs just as well [34], with a modification to  
272 include a calibration factor to correct for the variability of sCr measures across laboratories and  
273 time [35]:  $eGFR = 186.3 \times (sCr - 0.24)^{-1.154} \times Age^{-0.203} \times (0.742 \text{ if Female})$ .

274 For both eGFR and sU, we took a *log* transformation to normalize their distributions and  
275 preadjusted by age, sex, and the first 5 SNP-derived principal components using ordinary least  
276 squares.

277

### 278 **LBR model specification**

279 Following Funkhouser *et al.* [17], we fit a series of LBR models based on a core chunk of  
280 10,000 contiguous SNPs, and an overlapping flanking buffer of 500 SNPs taking the form of  
281  $y_i = \sum_{j=1}^p X_{ij}\beta_j + \varepsilon_i$  for  $p=11,000$  (core SNPs plus two flanking buffers). This method will be a  
282 robust substitute for a single whole-genome regression since LD spans over relatively short  
283 regions of SNPs in the UK Biobank Axiom<sup>TM</sup> Array and a homogeneous unstructured sample  
284 like the one used here [17]. Each LBR utilizes the BGLR R package [18] with a BayesC prior for  
285 the SNP effects, which has a point mass at zero and Gaussian slab. This prior performs variable  
286 selection to zero-out some SNPs and reduce the number of SNPs entering the model [36]. The  
287 Markov chain Monte Carlo algorithm for BayesC involves a Gibbs-sampler sequence of steps  
288 with the full-conditional posterior distributions [36]. The Markov chain Monte Carlo runs had  
289 long chains of 75,000 iterations, with a burn-in of 2,000 samples and thin of 5 that were  
290 discarded.

291

### 292 **LBR implementation**



293 The LBR had the following phenotypes as the response variable: sU ( $y_1$ ), eGFR ( $y_2$ ), and  
294 sU + eGFR ( $y_3$ ). For each of these three response models, we ran the LBR models across the  
295 genome, and obtained genetic variance estimates within each LD segment. That is, for each  $y_i$   
296 model, we estimated the genetic variance for each LD segment as  $\sigma_g^2 = \frac{\beta' X' X \beta}{n-1}$ , using only the  
297 SNPs within each LD segment. This allows us to then obtain a point estimate for the genetic  
298 covariance within each LD segment, we leveraged the fact that

$$299 \text{Cov}(y_1, y_2) = \frac{\text{Var}(y_1+y_2) - \text{Var}(y_1) - \text{Var}(y_2)}{2}.$$

300 Since each variance component comes from a separate series of LBR models, even  
301 though we have interval estimates for each of the three variance components, we cannot directly  
302 obtain an interval estimate for the covariance between sU and eGFR since there is not a closed  
303 form solution for the standard error estimates for the genetic covariance estimates. Therefore, we  
304 obtained interval estimates for select LD segments with a resampling method (described below).  
305 A visual summary of the local covariance pipeline can be found in S1 Fig.

306

### 307 **Defining local, LD-based segments**

308 Local genetic covariance inference from an individual SNP is problematic due to  
309 underlying LD structures, so we identified SNP regions in strong LD, and obtained variance  
310 estimates based on these LD segments of SNPs rather than using single individual SNPs [17].  
311 We used an overlapping sliding technique to obtain these local LD segments [16,17]. For each  
312 seed SNP  $\mathbf{x}_j$ , we sequentially identify SNPs in both directions ( $\mathbf{x}_{j^*}$ ) surrounding the seed SNP and  
313 include them in segment  $j$  if  $\text{Corr}(\mathbf{x}_j, \mathbf{x}_{j^*}) \geq 0.1$ . In a simplified example, if SNP  $\mathbf{x}_j$  has adequate  
314 pairwise correlation with 2 SNPs to the left, and 1 SNP to the right, the segment for that SNP  
315 would be defined as the set of SNPs:  $\{\mathbf{x}_{j-2}, \mathbf{x}_{j-1}, \mathbf{x}_j, \mathbf{x}_{j+1}\}$ . That is,  $\text{Corr}(\mathbf{x}_j, \mathbf{x}_{j-1}) \geq 0.1$  and  $\text{Corr}(\mathbf{x}_j,$

316  $x_{j-2}) \geq 0.1$  and  $\text{Corr}(x_j, x_{j+1}) \geq 0.1$ . However, our algorithm also involved an allowance for one  
317 SNP in the sequential process to not meet this correlation criterion, to allow for a brief loss of  
318 LD or minor mapping errors, and the SNP was still included in the LD segment. Continuing with  
319 the previous example, even if  $\text{Corr}(x_j, x_{j-1}) < 0.1$ , if  $\text{Corr}(x_j, x_{j-2}) \geq 0.1$ , then the set would still  
320 include both  $x_{j-2}$  and  $x_{j-1}$ . The LD block ends when two SNPs sequentially did not meet the  
321 criteria described above.

322

### 323 **Confidence interval estimates of the local covariances**

324 We estimated CIs for the most interesting LD regions based on bootstrapping methods.  
325 Because of the computational demands required by bootstrap resampling techniques with very  
326 large sample sizes, we preselected peaks to limit the CI estimates only to regions of interests. We  
327 considered GWAS significant variants for sU and CKD markers (sCr and eGFR) as indicators of  
328 loci considered regions of interest, so we applied a 100-SNP buffer to each side of each GWAS  
329 locus. All LBR regions of the SNPs of interest plus contiguous flanking SNPs were included in  
330 the model. The LBR models were identical to the description above (LBR model specification).  
331 We ran 200 bootstrap replicates using a sample of size  $n=333,542$  with replacement for each  
332 response model and averaged the iterations to obtain bootstrap covariance estimates. We  
333 obtained the 2.5% and 97.5% quantiles from the iterations to obtain 95% CIs for the bootstrap  
334 covariance estimates (Table 1 and S1 Table).

335

### 336 **Multiple testing adjustment**

337 Statistical significance was also conservatively estimated based on a Bonferroni multiple  
338 testing correction. We obtained normality-based p-values from a T-statistic from our

339 bootstrapped covariance estimates and divided that by the standard error estimates obtained from  
340 the standard deviation of the bootstrap iterations. This value was then compared to the standard  
341 normal distribution. We performed this on 14,802 LD regions, which determined the  
342 conservative Bonferroni multiple testing adjustment.

343

## 344 **Genome-Wide Association Studies**


345 GWAS were performed to identify SNPs significantly associated with sU and sCr using  
346 single marker linear regression models in the UK Biobank sample. Each GWAS was performed  
347 for  $k=607,490$  SNPs that passed quality control (described above). The sU GWAS used a sample  
348 size of  $n=288,831$  unrelated, white participants. Participants were excluded from the sU GWAS  
349 if they were missing the sU phenotype, if they were not between the ages of 40 and 69 years old,  
350 if their genotypes did not pass quality control, and if they had a primary or secondary diagnosis  
351 of kidney disease. The sCr GWAS used a sample size of  $n=301,594$  distantly related, white  
352 participants. Participants were excluded from the sCr GWAS if they were missing the sCr  
353 phenotype. Both GWAS were performed using the following model for each SNP variant  $j=\{1,$   
354  $\dots, k\}$ :  $\mathbf{y} = \boldsymbol{\mu} + \mathbf{X}\boldsymbol{\beta} + \mathbf{W}_i\mathbf{s}_i + \boldsymbol{\varepsilon}$ , where  $\mathbf{y}=(y_1, \dots, y_n)'$  is the vector of phenotypic observations for  
355 sU, eGFR, or sCr,  $\boldsymbol{\mu}$  is a vector of the overall mean, and  $\mathbf{X}$  is a design matrix connecting the  
356 fixed effect levels to the observations. The fixed effects included sex, age, and the first 5 SNP-  
357 derived principal components. Additionally,  $\boldsymbol{\beta}$  is a vector with the corresponding effects,  $\mathbf{W}_i$  is a  
358 vector with the  $j^{\text{th}}$  SNP,  $\mathbf{s}_i$  is the additive genetic effect of the  $j^{\text{th}}$  SNP, and  $\boldsymbol{\varepsilon}=(\varepsilon_1, \dots, \varepsilon_n)'$  is the  
359 vector of the residuals. A variant was considered significant if it had a p-value  $< 5e-8$ . The  
360 GWAS summary statistics can be found in S2 Table.

361


## 362 **Gene expression/eQTL analysis**

363 A colocalization analysis was performed between GWAS significant markers for sU and  
364 sCr and the publicly available eQTL data from GTEx v8 [19]. The R package COLOC was used,  
365 which implements a Bayesian test that analyses a single genomic region and identifies LD  
366 patterns in that locus using SNP summary statistics and the associated minor allele frequencies.  
367 The lead variant for both sCr and sU was used at each significant covariance segment with a  
368 surrounding 500 kb buffer in the GTEx database. The Contextualizing Developmental SNPs  
369 using 3D Information algorithm [37,38] was modified to identify long-distance regulatory  
370 relationships for the lead sU and sCr variants at each significant covariance segment within a 500  
371 kb window. eQTL data for variants +/- 500 kb of the lead variant were also extracted from GTEx  
372 and then COLOC was used to assess if the significant *cis*- and *trans*-eQTL identified were  
373 colocalized with sCr and sU signals. The eQTL was required to have a posterior probability of  
374 causality (PPC) of at least 0.5 for both traits, along with a PPC of at least 0.8 for one of the two  
375 traits.  
376

377 A.




378 **B.**




379

380 **Fig 1.** The variance estimates of LD segments in the unrelated white cohort of the UK Biobank

381 for sU concentrations (A) and eGFR (B).



382  
383 **Fig 2.** Covariance estimates of LD segments in UK Biobank, selectively annotated with the gene  
384 name of the mid-point SNP of that segment and the segment size. Segments that contained SNPs  
385 in loci associated with known eGFR genes are highlighted in dark green, segments that contained  
386 SNPs in genes associated with sU are highlighted in blue, and segments that contained SNPs in  
387 genes associated with both sU and eGFR (from comparing separate GWAS, Johnson et al. [21])  
388 are highlighted in lime green. Segments significant for genetic covariance are highlighted in red.



389  
 390 **Fig 3.** Figure of top 29 implicated significant shared loci (the distinct loci derived from the top  
 391 50 results) and their effects with corresponding 95% confidence intervals. The figure contains  
 392 results from LD genomic regions with confidence intervals band not including 0. Segment size  
 393 indicates the number of SNPs in the implicated loci segment selected (largest segment if overlaps  
 394 existed).



395 **Supporting information captions**

396

397 **S1 Fig.** A visual summary of our methodology to obtain covariance estimates between sU and  
398 eGFR.

399

400 **S1 Table.** The effect sizes with corresponding confidence intervals, significance, the  
401 directionality of the association, and validations for all significant covariance regions.

402

403 **S2 Table.** The results from a UK Biobank GWAS in sU and sCr.

404

405 **S3 Table.** The 188 distinct loci implicated by the LD segments significant for genetic  
406 covariance, with eQTLs.

407

408 **S4 Table.** The eQTLs that colocalized with the sU and eGFR covariance signals.

409

## 410 **Acknowledgments**

411 This study was funded by the National Institute of Arthritis and Musculoskeletal and Skin  
412 Diseases P50AR060772 (Insight CORT), and by Michigan State University. The Contextualizing  
413 Developmental SNPs using 3D Information algorithm was run on computing resources provided  
414 by the University of Auckland. JOS and TF were funded by the Dines Family Charitable Trust  
415 and HRC Explorer Grant (HRC 19/774). We would like to thank Michigan State University's  
416 High Performance Computing Cluster for providing all additional computing resources.

## 417 **References**

- 418 1. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional,  
419 and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the  
420 Global Burden of Disease Study 2017. *The Lancet*. 2020 Feb;395(10225):709–33.
- 421 2. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global  
422 Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis.  
423 Remuzzi G, editor. *PLOS ONE*. 2016 Jul 6;11(7):e0158765.
- 424 3. Chronic Kidney Disease Basics | Chronic Kidney Disease Initiative | CDC [Internet]. 2019  
425 [cited 2019 Aug 8]. Available from: <https://www.cdc.gov/kidneydisease/basics.html>
- 426 4. Sun M, Vazquez AI, Reynolds RJ, Singh JA, Reeves M, Merriman TR, et al. Untangling  
427 the complex relationships between incident gout risk, serum urate, and its comorbidities.  
428 *Arthritis Res Ther*. 2018 May 3;20(1):90.
- 429 5. Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends.  
430 *Rheumatology*. 2019 Dec 1;58(12):2177–80.
- 431 6. Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of  
432 vascular disease associated with gout: a retrospective, matched cohort study in the UK  
433 clinical practice research datalink. *Ann Rheum Dis*. 2015 Apr;74(4):642–7.
- 434 7. Kuo C-F, Luo S-F. Gout: Risk of premature death in gout unchanged for years. *Nat Rev*  
435 *Rheumatol*. 2017 Apr;13(4):200–1.
- 436 8. Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD. Health-related  
437 quality of life in gout: a systematic review. *Rheumatol Oxf Engl*. 2013 Nov;52(11):2031–  
438 40.
- 439 9. Jing J, Ekici AB, Sitter T, Eckardt K-U, Schaeffner E, Li Y, et al. Genetics of serum urate  
440 concentrations and gout in a high-risk population, patients with chronic kidney disease. *Sci*  
441 *Rep*. 2018 Dec;8(1):13184.
- 442 10. Zhu Y, Pandya BJ, Choi HK. Comorbidities of Gout and Hyperuricemia in the US General  
443 Population: NHANES 2007-2008. *Am J Med*. 2012 Jul;125(7):679-687.e1.
- 444 11. Tin A, Marten J, Halperin Kuhns VL, Li Y, Wuttke M, Kirsten H, et al. Target genes,  
445 variants, tissues and transcriptional pathways influencing human serum urate levels. *Nat*  
446 *Genet*. 2019;51(10):1459–74.
- 447 12. Reynolds RJ, Irvin MR, Bridges SL, Kim H, Merriman TR, Arnett DK, et al. Genetic  
448 correlations between traits associated with hyperuricemia, gout, and comorbidities. *Eur J*  
449 *Hum Genet* [Internet]. 2021 Feb 26 [cited 2021 Mar 29]; Available from:  
450 <http://www.nature.com/articles/s41431-021-00830-z>

- 451 13. Shi H, Mancuso N, Spendlove S, Pasaniuc B. Local Genetic Correlation Gives Insights into  
452 the Shared Genetic Architecture of Complex Traits. *Am J Hum Genet.* 2017  
453 Nov;101(5):737–51.
- 454 14. Leask MP, Sumpter NA, Lupi AS, Vazquez AI, Reynolds RJ, Mount DB, et al. The Shared  
455 Genetic Basis of Hyperuricemia, Gout, and Kidney Function. *Semin Nephrol.* 2020  
456 Nov;40(6):586–99.
- 457 15. Vilhjálmsson BJ, Yang J, Finucane HK, Gusev A, Lindström S, Ripke S, et al. Modeling  
458 Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. *Am J Hum Genet.*  
459 2015 Oct;97(4):576–92.
- 460 16. Fernando R, Toosi A, Wolc A, Garrick D, Dekkers J. Application of Whole-Genome  
461 Prediction Methods for Genome-Wide Association Studies: A Bayesian Approach. *J Agric  
462 Biol Environ Stat.* 2017 Jun;22(2):172–93.
- 463 17. Funkhouser SA, Vazquez AI, Steibel JP, Ernst CW, los Campos G de. Deciphering Sex-  
464 Specific Genetic Architectures Using Local Bayesian Regressions. *Genetics.* 2020  
465 May;215(1):231–41.
- 466 18. Pérez P, de los Campos G. Genome-wide regression and prediction with the BGLR  
467 statistical package. *Genetics.* 2014 Oct;198(2):483–95.
- 468 19. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al.  
469 Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using  
470 Summary Statistics. Williams SM, editor. *PLoS Genet.* 2014 May 15;10(5):e1004383.
- 471 20. Carithers LJ, Moore HM. The Genotype-Tissue Expression (GTEx) Project.  
472 *Biopreservation Biobanking.* 2015 Oct;13(5):307–8.
- 473 21. Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanasa MA, et al.  
474 Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular  
475 Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.  
476 *Am J Kidney Dis Off J Natl Kidney Found.* 2018;71(6):851–65.
- 477 22. Major TJ, Dalbeth N, Stahl EA, Merriman TR. An update on the genetics of  
478 hyperuricaemia and gout. *Nat Rev Rheumatol.* 2018;14(6):341–53.
- 479 23. Hughes K, Flynn T, de Zoysa J, Dalbeth N, Merriman TR. Mendelian randomization  
480 analysis associates increased serum urate, due to genetic variation in uric acid transporters,  
481 with improved renal function. *Kidney Int.* 2014 Feb;85(2):344–51.
- 482 24. Yang Q, Köttgen A, Dehghan A, Smith AV, Glazer NL, Chen M-H, et al. Multiple Genetic  
483 Loci Influence Serum Urate Levels and Their Relationship With Gout and Cardiovascular  
484 Disease Risk Factors. *Circ Cardiovasc Genet.* 2010 Dec;3(6):523–30.

- 485 25. Köttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, et al. Genome-  
486 wide association analyses identify 18 new loci associated with serum urate concentrations.  
487 Nat Genet. 2013 Feb;45(2):145–54.
- 488 26. Dehghan A, Köttgen A, Yang Q, Hwang S-J, Kao WL, Rivadeneira F, et al. Association of  
489 three genetic loci with uric acid concentration and risk of gout: a genome-wide association  
490 study. The Lancet. 2008 Dec;372(9654):1953–61.
- 491 27. Cho SK, Kim B, Myung W, Chang Y, Ryu S, Kim H-N, et al. Polygenic analysis of the  
492 effect of common and low-frequency genetic variants on serum uric acid levels in Korean  
493 individuals. Sci Rep. 2020 Dec;10(1):9179.
- 494 28. Wuttke M, Y Li, M Li. A catalog of genetic loci associated with kidney function from  
495 analyses of a million individuals. Nat Genet. 2019;51:957–72.
- 496 29. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic  
497 genetic variants to estimate causal effects. Am J Epidemiol. 2015 Feb 15;181(4):251–60.
- 498 30. Jordan DM, Choi HK, Verbanck M, Topless R, Won H-H, Nadkarni G, et al. No causal  
499 effects of serum urate levels on the risk of chronic kidney disease: A Mendelian  
500 randomization study. PLoS Med. 2019;16(1):e1002725.
- 501 31. Affymetrix. Genetic data: Detailed genetic data on half a million people [Internet]. 2021  
502 [cited 2021 Mar 4]. Available from: [http://www.ukbiobank.ac.uk/scientists-3/uk-biobank-  
503 axiom-array/](http://www.ukbiobank.ac.uk/scientists-3/uk-biobank-axiom-array/)
- 504 32. Kim H, Grueneberg A, Vazquez AI, Hsu S, de Los Campos G. Will Big Data Close the  
505 Missing Heritability Gap? Genetics. 2017;207(3):1135–45.
- 506 33. Grueneberg A, de los Campos G. BGData - A Suite of R Packages for Genomic Analysis  
507 with Big Data. G3amp58 GenesGenomesGenetics. 2019 May;9(5):1377–83.
- 508 34. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new  
509 equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604–  
510 12.
- 511 35. Coresh J, Astor BC, McQuillan G, Kusek J, Greene T, Van Lente F, et al. Calibration and  
512 random variation of the serum creatinine assay as critical elements of using equations to  
513 estimate glomerular filtration rate. Am J Kidney Dis. 2002 May;39(5):920–9.
- 514 36. Habier D, Fernando RL, Kizilkaya K, Garrick DJ. Extension of the bayesian alphabet for  
515 genomic selection. BMC Bioinformatics. 2011 Dec;12(1):186.
- 516 37. Fadason T, Schierding W, Lumley T, O’Sullivan JM. Chromatin interactions and  
517 expression quantitative trait loci reveal genetic drivers of multimorbidities. Nat Commun.  
518 2018 Dec;9(1):5198.

519 38. Genome3d/codes3d-v2 [Internet]. Genome3d; 2019 [cited 2021 Mar 31]. Available from:  
520 <https://github.com/Genome3d/codes3d-v2>

521

522